Pembrolizumab in Combination with Folfirinox for Treatment of Advanced Pancreatic Adenocarcinoma With MSI-H

Pancreatic cancer is one of the four most common causes of cancer-related death in the United States. Our patient had metastatic pancreatic cancer with a high tumour burden. He was trialled on an unconventional treatment of combination immunotherapy and chemotherapy. It resulted in decreased cancer...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of case reports in internal medicine Vol. 11; no. 10; p. 004767
Main Authors Singh, Ashmin, Sanghavi, Nairuti, Bandari, Vandana, Khan, Iftekhar, Alfaraj, Abeer
Format Journal Article
LanguageEnglish
Published Italy SMC Media Srl 24.09.2024
SMC MEDIA SRL
Subjects
msi-h
pancreatic adenocarcinoma
pembrolizumab
pancreatic adenocarcinoma
pembrolizumab
MSI-H
Online AccessGet full text

Cover

More Information
Summary:Pancreatic cancer is one of the four most common causes of cancer-related death in the United States. Our patient had metastatic pancreatic cancer with a high tumour burden. He was trialled on an unconventional treatment of combination immunotherapy and chemotherapy. It resulted in decreased cancer burden and decreased FDG activity on a PET scan. Further studies are needed for standard pancreatic cancer treatment. Very few patients survive pancreatic cancer, especially metastatic disease. Our patient is doing very well after a few years.There is little evidence for concurrent use of chemotherapy and immunotherapy. Our patient received it and has had no new lesions, and there has been an improvement on imaging.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2284-2594
2284-2594
DOI:10.12890/2024_004767